AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...

AstraZeneca PLC (AZN) reports an 11% revenue increase, driven by oncology and biopharmaceuticals, while navigating R&D ...

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

Investing.com -- AstraZeneca PLC (ST:AZN) announced Tuesday that its drug Koselugo (selumetinib) has received European Union ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

WASHINGTON (AP) — AstraZeneca on Friday became the second major pharmaceutical manufacturer to announce it had agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the ...

(MENAFN- GlobeNewsWire - Nasdaq) The nasal polyps market presents opportunities with multiple pipeline drugs in various development stages, targeting novel treatment approaches. Focused efforts by key ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC ...

AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, ...

AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector ...